SCHEMBL27217046

SCHEMBL27217046

CCn1nc(I)c(-c2ccccc2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.41
▸ CASP1 P29466 3/20 0.41
▸ CASP7 P55210 3/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ ATM Q13315 2/20 0.41
▸ CRHBP P24387 2/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ CRHR2 Q13324 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ TNNI3 P19429 1/20 0.41
▸ TNNT2 P45379 1/20 0.41
▸ TNNC1 P63316 1/20 0.41
▸ KEAP1 Q14145 1/20 0.41
▸ NFE2L2 Q16236 1/20 0.41
▸ TLR9 Q9NR96 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ PDE4A P27815 2/20 0.39
▸ PDE4B Q07343 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13243234 0.86 KMT2A (0.47) KDM4ECASP1CASP7MEN1KMT2A
SCHEMBL17280145 0.78 CASP1 (0.42) KDM4ECASP1CASP7MEN1KMT2A
SCHEMBL13510721 0.77 NR1H3 (0.44) KDM4ECASP1CASP7MEN1KMT2A
SCHEMBL14294733 0.76 NR1H2 (0.54) KDM4ECASP1CASP7MEN1KMT2A
SCHEMBL13510678 0.74 MAPT (0.42) KDM4ECASP1CASP7MEN1KMT2A
SCHEMBL24828265 0.73 — —
SCHEMBL13510724 0.73 KDM4E (0.57) KDM4EMEN1KMT2AATMTDP1
SCHEMBL13510688 0.73 LTA4H (0.47) KDM4EATMTDP1L3MBTL1ALDH1A1
SCHEMBL13510494 0.72 ADORA2A (0.50) KDM4ECASP1CASP7MEN1KMT2A
SCHEMBL13510674 0.72 CYP2A6 (0.50) KDM4ECASP1CASP7MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584259-A1 CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS Innovo Therapeutics, Inc. (US) 2025-07-16 — — EP disclosed
US-20240158370-A1 CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS INNOVO THERAPEUTICS, INC. 2024-05-16 — — US disclosed
WO-2024054832-A1 CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS INNOVO THERAPEUTICS, INC. (US) 2024-03-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158370-A1 CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS CKS1B, CKS2, MARK1 KDM4E 1794/4885CASP1 250/4885CASP7 2973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback